19F MRI-Based Imaging of Thromboinflammatory Processes in Cardiovascular Diseases

Sebastian Temme^1,2, Patricia Kleimann ², Pascal Bouvain², Arthur Zielinski², Jeny Koshy², Mina Yakoub³, Florian Bönner ⁴, Christoph Jacoby⁵, Francesca Baldelli-Bombelli ⁶, Karlheinz Peter⁷, Xiaowei Wang⁸, Jürgen Schrader⁹, Johannes Stegbauer³, and Ulrich Flögel²
¹Anaesthesiology, University Hospital Düsseldorf, Düsseldorf, Germany, ²Experimental Cardiovascular Imaging, Heinrich-Heine-University, Düsseldorf, Germany, ³Experimental Nephrology, University Hospital Düsseldorf, Düsseldorf, Germany, ⁴Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine-University, Düsseldorf, Germany, ⁵Cardiology, Pulmonology and Vascular Medicine, University Hospital Düsseldorf, Düsseldorf, Germany, ⁶Chemistry, Materials and Chemical Engineering, Politechnico Milano, Milano, Italy, ⁷Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, Australia, ⁸Molecular Imaging and Theranostics, Baker Heart and Diabetes Institute, Melbourne, Australia, ⁹Molecular Cardiology, Heinrich-Heine-University, Düsseldorf, Germany

Synopsis

Thromboinflammation is characterized by a close interaction of immune cells, platelets and components of the coagulation cascade. This impairs the systemic spread of pathogens, but can also foster the development and progression of cardiovascular diseases like deep vein thrombosis, atherosclerosis or myocardial infarction. Non-invasive visualization of thromboinflammation is challenging, because it requires the simultaneous imaging of thrombosis and immune cells. In this context, ¹⁹F MRI offers unique opportunities because of the large chemical shift range of the ¹⁹F-atoms and the availability of perfluorocarbons with individual spectral signatures that enables the visualization of thromboinflammatory processes by multispectral ¹⁹F MRI.

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (UF: SFB 1116, TRR 259, FL303/6-1/2, INST 208/764-1 FUGG and ST: TE1209/1-1/2) and the European Commission (MSCA-ITN-2019 ‘NOVA-MRI’, MSCA-RISE-2019 ‘PRISAR2 to U.F.).

References

No reference found.

Proc. Intl. Soc. Mag. Reson. Med. 30 (2022)